Brian Shuch

/in /by


Brian Shuch, Ph.D.


Office Address:
300 Stein Plaza, 3rd Floor

Affiliations

Professor, Molecular, Cell, and Developmental Biology
Member, Brain Research Institute, Cell & Developmental Biology GPB Home Area, Neuroscience GPB Home Area
Research Interests

Kidney cancer is a diverse disease with unique somatic and germline variants responsible for 18 current subtypes. Many of these alter the fundamental metabolism of kidney tumors, some of which can be exploited therapeutically. We currently are studying studying two types of kidney tumors that have complex I loss. One in particular, HLRCC, results from a germline variant in the Fumarate hydratase gene. We helped describe FH as a gene involved in homologous recombination and are now exploiting this in the lab and clinically. Other collaborations are working with the Shackelford team to evaluate glutaminase inhibition and the Christofk lab for asparaginase inhibition in these models. We are motivated to define and exploit drivers in our kidney cancer models systems to advance to clinical use as soon as possible.

Publications

A selected list of publications:

Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. iScience. 2022 Jun 17; 25(6):104463. Jikuya R, Murakami K, Nishiyama A, Kato I, Furuya M, Nakabayashi J, Ramilowski JA, Hamanoue H, Maejima K, Fujita M, Mitome T, Ohtake S, Noguchi G, Kawaura S, Odaka H, Kawahara T, Komeya M, Shinoki R, Ueno D, Ito H, Ito Y, Muraoka K, Hayashi N, Kondo K, Nakaigawa N, Hatano K, Baba M, Suda T, Kodama T, Fujii S, Makiyama K, Yao M, Shuch BM, Schmidt LS, Linehan WM, Nakagawa H, Tamura T, Hasumi H. PMID: 35874919; PMCID: PMC9301876.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 01; 20(1):71-90. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. PMID: 34991070.
Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. Cancer. 2022 02 15; 128(4):675-684. Lu E, Hatchell KE, Nielsen SM, Esplin ED, Ouyang K, Nykamp K, Zavoshi S, Li S, Zhang L, Wilde BR, Christofk HR, Boutros PC, Shuch B. PMID: 34724198; PMCID: PMC9170268.
Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. Am J Clin Pathol. 2021 Sep 08; 156(4):550-558. Yang C, Shuch B, Kluger HM, Serrano M, Kibel AS, Humphrey PA, Adeniran AJ. PMID: 34424955.
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer. 2021 Nov 01; 127(21):3957-3966. Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, Rathmell WK, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B. PMID: 34343338; PMCID: PMC8711633.
Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. Radiographics. 2021 Sep-Oct; 41(5):1387-1407. Abou Elkassem AM, Lo SS, Gunn AJ, Shuch BM, Dewitt-Foy ME, Abouassaly R, Vaidya SS, Clark JI, Louie AV, Siva S, Grosu AL, Smith AD. PMID: 34270355.
Papillary renal cell carcinoma: Review. Urol Oncol. 2021 06; 39(6):327-337. Mendhiratta N, Muraki P, Sisk AE, Shuch B. PMID: 34034966.
Reply to Alexa R. Meyer, Steven P. Rowe, and Nirmish Singla’s Letter to the Editor re: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol 2021;79:107-11. Integrating 99mTc-sestamibi and ONEX to Optimize Risk Stratification for Renal Masses. Eur Urol. 2021 07; 80(1):e22-e23. Shuch B, Raman S, Calais J. PMID: 33941405.
68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2021 10; 48(11):3736-3737. Hotta M, Sonni I, Benz MR, Gafita A, Bahri S, Shuch BM, Yu R, Liu ST, Czernin J, Calais J. PMID: 33914106.
HIF2 Inhibition for von-Hippel Lindau Associated Kidney Cancer: Will Urology Lead or Follow? Urol Oncol. 2021 05; 39(5):277-280. Shuch B. PMID: 34297683.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021 02 20; 397(10275):695-703. Pal SK, Tangen C, Thompson IM, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN. PMID: 33592176; PMCID: PMC8687736.
Advances in the Characterization of Clear Cell Papillary Renal Cell Carcinoma: Identifying the Sheep in Wolf’s Clothing. Eur Urol. 2021 04; 79(4):478-479. Filippou P, Shuch B, Psutka SP. PMID: 33579573.
Telemedicine-Based Perioperative Management of Pheochromocytoma in a Patient With Von Hippel Lindau Disease: A Case Report. A A Pract. 2021 Jan 14; 15(1):e01378. Saksa D, Shuch B, Donahue T, Cusumano L, Yu R, Alapag C, Kamdar N. PMID: 33512909.
Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. Eur Urol Oncol. 2021 02; 4(1):22-41. Campi R, Stewart GD, Staehler M, Dabestani S, Kuczyk MA, Shuch BM, Finelli A, Bex A, Ljungberg B, Capitanio U. PMID: 33408053.
Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography. Cancers (Basel). 2020 Oct 16; 12(10). Uhlig J, Leha A, Delonge LM, Haack AM, Shuch B, Kim HS, Bremmer F, Trojan L, Lotz J, Uhlig A. PMID: 33081400; PMCID: PMC7603020.
Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol. 2021 01; 79(1):107-111. McGillivray PD, Ueno D, Pooli A, Mendhiratta N, Syed JS, Nguyen KA, Schulam PG, Humphrey PA, Adeniran AJ, Boutros PC, Shuch B. PMID: 32972793; PMCID: PMC8939926.
Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncol Pract. 2020 11; 16(11):e1264-e1271. Bergerot CD, Battle D, Philip EJ, Bergerot PG, Msaouel P, Smith A’, Bamgboje AE, Shuch B, Derweesh IH, Jonasch E, Stern AP, Pal SK, Staehler M. PMID: 32955409.
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020 09; 18(9):1160-1170. Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. PMID: 32886895.
Analysis of guideline recommended use of renal mass biopsy and association with treatment. Can J Urol. 2020 08; 27(4):10285-10293. Michel J, Lenis AT, Lec PM, Golla V, Johnson DC, Gollapudi K, Blumberg J, Shuch BM, Chamie K. PMID: 32861253.
Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma. Urol Clin North Am. 2020 Aug; 47(3):345-358. Wood E, Donin N, Shuch B. PMID: 32600536.